Related Experiment Video
Updated: Jan 15, 2026

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma
Supreet Singh1, Lucy C Campbell1, Ike S Okwuosa1
1Division of Cardiovascular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Background:
Filamin C (FLNC) variants are often associated with structural cardiomyopathies but rarely myocarditis.
Case Summary:
A 60-year-old man with newly diagnosed B-cell lymphoma and initiation of cancer therapy presented with substernal chest pain. He had experienced myocarditis 2 years ago from a COVID-19 vaccine or possible infection; however, he received another COVID-19 booster in anticipation of upcoming cancer therapy. He was diagnosed with acute myocarditis, and his course was complicated by cardiac arrest requiring multidisciplinary management. Outpatient genetic testing revealed a pathogenic FLNC variant.
Discussion:
This report highlights the case of a patient with FLNC mutation who developed recurrent myocarditis in the setting of exogenous factors, including the COVID-19 vaccine and a history of lymphoma and immunotherapy.
Take-Home Messages:
Myocarditis may be the initial presentation for certain genetic cardiomyopathies. Genetic testing should be strongly considered in patients with multiple episodes of myocarditis.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Pericarditis I: Introduction
Pericarditis III: Medical Management

